GET DAILY SIGNALSOrchestra BioMed Holdings (OBIO): What to Watch for in Q3 2026 Results
Key Takeaways
- Orchestra BioMed Holdings (OBIO) is expected to report third quarter 2026 results in November 2026, with consensus earnings per share (EPS) near -$0.40.
- Revenue is expected to remain minimal as the clinical-stage company prioritizes its two lead programs, AVIM Therapy and Virtue SAB.
- Cash and marketable securities of roughly $110 million as of June 30, 2026, are expected to fund operations into the fourth quarter of 2027.
- Investors will focus on enrollment progress in the BACKBEAT pivotal trial, which was targeted for completion by the end of the third quarter of 2026.
- Research and development (R&D) spending has been rising, up 20% year over year in the second quarter of 2026, driven by increased clinical activity.
Earnings Context and Why It Matters
Orchestra BioMed Holdings is a biomedical company developing AVIM Therapy (Atrioventricular Interval Modulation), a bioelectronic treatment for hypertension delivered as a firmware upgrade to pacemakers, and Virtue SAB (Sirolimus AngioInfusion Balloon), a drug-delivery balloon for atherosclerotic artery disease. Because the company generates little revenue, quarterly results matter less for the top line than for the signals they send about cash runway and clinical execution. I am watching whether trial timelines remain on track, how R&D spending is trending, and whether the balance sheet can support the company through its next major data readouts. With pivotal data expected in 2027, this report is a key checkpoint on progress toward value-driving milestones.
Earnings Expectations
Analysts expect OBIO to report a net loss for the third quarter of 2026, with consensus EPS estimates clustered around -$0.40 and revenue forecasts near $0.1 million, reflecting the company's pre-commercial stage. For context, the company posted an EPS of -$0.38 and revenue of $88,000 in the second quarter of 2026, and an EPS of -$0.33 with revenue of $110,000 in the first quarter of 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Because revenue is not yet a meaningful driver, the market will likely pay closer attention to non-financial updates, including enrollment in the BACKBEAT global pivotal study for AVIM Therapy, which management aimed to complete by the end of the third quarter of 2026, and progress in the Virtue SAB pivotal trial. Cash position, R&D expense trends, and any updated guidance on the cash runway will also be closely scrutinized.
Market Reaction and Investor Sentiment
Heading into the third quarter 2026 report, sentiment around OBIO reflects a balance between optimism about its clinical pipeline and caution about its cash needs. The stock has shown sensitivity to clinical and partnership news, and the company's addition to the Russell 3000 and Russell 2000 indexes in June 2026 increased its visibility among institutional investors.
Key risk factors include the potential for trial delays, higher-than-expected R&D spending, and the possibility of future capital raises, which could pressure the share price. Because the company is not yet profitable, investors tend to react more to milestone announcements and cash runway commentary than to headline revenue figures.
Forward Outlook and Key Factors to Monitor
Following the third quarter report, the most important items to monitor are the completion of BACKBEAT trial enrollment and the timing of primary endpoint data, which is currently anticipated in the second quarter of 2027. Successful results could support a regulatory submission by partner Medtronic for AVIM Therapy and mark a major value inflection point for the company.
Investors should also track enrollment in the Virtue SAB pivotal trial, where full enrollment is targeted for 2027. Cost trends will matter as well, since rising R&D spending is expected to continue as both trials advance. Management has indicated that cash on hand should fund operations into the fourth quarter of 2027, so any change to that guidance would be a meaningful signal.
Finally, an R&D Day scheduled for November 12, 2026, will offer additional detail on the AVIM Therapy and Virtue SAB programs. Combined with the earnings release, these updates will help investors assess whether the company's clinical and financial trajectory remains on track ahead of its anticipated 2027 catalysts.
Exploring AI Tools in My Research Process
In my own work following clinical-stage names like OBIO, I regularly use Tickeron’s AI Screener to scan for comparable opportunities and monitor technical patterns across the sector. It helps surface ideas based on fundamentals, volatility, and AI-driven signals without replacing deeper fundamental review. This kind of tool adds efficiency when tracking trial progress and peer performance ahead of key updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OBIO saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for OBIO moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 56 similar instances where the indicator exited the overbought zone. In 45 of the 56 cases the stock moved lower. This puts the odds of a downward move at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for OBIO turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 30 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.
OBIO moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on OBIO as a result. In 64 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The 10-day moving average for OBIO crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +5.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where OBIO advanced for three days, in 164 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
OBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 130 of 181 cases where OBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.668) is normal, around the industry mean (3.498). P/E Ratio (-6.762) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.198) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement